How Synthetic Peptides Block Immune System Overreaction

A patent describing specific synthetic peptides designed to stop the body's immune system from attacking healthy cells by blocking a protein called C5.

What it covers

This patent describes a family of synthetic peptides—short chains of amino acids—that act as precision tools to modulate the complement system. The complement system is a part of the immune system that normally helps clear pathogens, but when overactive, it can cause severe inflammation and tissue damage. The claimed peptides include specific structures that use bridging moieties, such as aromatic rings or thioether bonds, to lock the peptide into a stable, cyclic shape. This shape allows the peptide to bind specifically to the C5 protein, preventing it from being cleaved into smaller, active parts that trigger immune attacks. By inhibiting this cleavage, these peptides can be used to treat conditions like paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome.

What it doesn't cover

• —Does not cover naturally occurring peptides found in the human body.
• —Does not cover general methods of protein synthesis not involving these specific sequences.
• —Does not cover non-peptide inhibitors of the complement system.
• —Does not cover treatments for diseases not related to complement system activity.

The clever bit

The innovation lies in the use of synthetic 'bridging moieties' to force flexible peptides into rigid, cyclic shapes, which significantly increases their binding affinity and stability in the bloodstream compared to linear peptides.

Why it matters

The complement system is implicated in a wide range of autoimmune and inflammatory diseases. By developing small, stable peptides that can be administered as drugs, researchers can target specific immune pathways with high precision, potentially offering alternatives to larger, more complex antibody-based therapies.

Real-world examples

• 1.Zilucoplan
• 2.Treatments for paroxysmal nocturnal hemoglobinuria
• 3.Therapies for atypical hemolytic uremic syndrome